Discover our cGMP-compliant research and commercial-grade chemical building blocks, peptide raw materials, and specialized industrial intermediates.
An authoritative analysis of nucleoside chemistries driving next-generation mRNA vaccines, RNA interference (RNAi) therapeutics, and enzymatic synthesis architectures.
In the evolving biopharmaceutical landscape, Pseudouridine (CAS 1445-07-0) and its precursor Uridine (CAS 58-96-8) have emerged as critical structural building blocks. Pseudouridine, an isomer of the nucleoside uridine in which the uracil base is attached via a carbon-carbon (C-C) glycosidic bond rather than a nitrogen-carbon (N-C) linkage, represents the most abundant naturally occurring modified RNA base. In modern commercial applications, wholesale procurement of high-purity uridine derivatives dictates the scalability, cost-efficiency, and therapeutic efficacy of mRNA vaccines, oncology therapies, and gene-editing platforms.
As global pharmaceutical enterprises shift toward scalable biomanufacturing, selecting validated Pseudouridine and Uridine factories capable of maintaining metric-ton scale production with ultra-low impurity profiles (HPLC purity ≥ 99.5%) is a imperative strategic objective. Gentolex Group sits at the nexus of this revolution, combining raw material sovereignty, chemical synthesis optimization, and cGMP compliance.
Evaluating the technological transition from traditional chemical synthesis to green enzymatic cascade catalysis.
Transitioning from classical C-glycosylation chemical synthesis to bi-enzymatic conversion using recombinant uridine phosphorylase (UP) and pseudouridine synthase (TruB). This achieves 98%+ conversion yields with zero heavy metal contaminants.
Implementing microfluidic continuous flow reactors for C-C glycosidic bond formation, eliminating batch-to-batch variation, improving safety profiles, and reducing thermal degradation during scaling.
Expanding production vectors into N1-Methylpseudouridine 5'-triphosphate (m1ΨTP), 5-Methoxyuridine (5moU), and 2'-O-Methyluridine to support tailored mRNA secondary structures and extended intracellular half-lives.
Deployment of high-field NMR (600 MHz) and LC-MS/MS protocols to identify and suppress ribosyl-migration isomers and beta-anomer impurities down to < 0.01% w/w.
| Synthesis Route | Typical Yield (%) | Beta/Alpha Anomer Ratio | Environmental Footprint (E-Factor) | Scalability Rating |
|---|---|---|---|---|
| Legacy Chemical Synthesis | 45% - 62% | 85 : 15 (Requires Column Separation) | High (> 120) | Moderate (High Solvent Usage) |
| Gentolex Continuous Flow Chem | 78% - 85% | 96 : 4 | Medium (∼ 45) | High (Automated Process Control) |
| Gentolex Bio-Enzymatic Platform 4.0 | 94% - 98% | 100 : 0 (Stereospecific) | Ultra-Low (< 8) | Industrial Metric-Ton Scale |
Customized raw material architectures for biopharmaceutical entities, contract development and manufacturing organizations (CDMOs), and research facilities.
Supply of commercial-grade Pseudouridine and m1ΨTP compliant with global pharmacopeias. Our materials guarantee minimal double-stranded RNA (dsRNA) formation during in vitro transcription (IVT), significantly enhancing protein translation efficacy in host cells.
Engineered Uridine phosphoramidites tailored for solid-phase RNA synthesis. Essential for siRNA and antisense oligonucleotide (ASO) platforms targetting rare metabolic disorders, liver therapeutics, and oncology targets.
Ultra-pure synthetic Uridine derivatives designed for synthetic single-guide RNA (sgRNA). Modified nucleosides enhance nuclease resistance and minimize off-target cleavage events in vivo.
An overall factory construction area of 250,000 square meters under international standard to offer flexible, scalable and cost-effective solutions.
Gentolex offers an extensive range of APIs and intermediates for development study and commercial application with cGMP standard from long-term collaborations. Documents and Certificates are supported to customers worldwide.
Comprehensive contract research and synthesis capabilities for novel nucleosides, modified nucleotides, and complex peptide structures from mg to metric tons.
For those clients who prefer to avoid the complexity of dealing with multiple points of contact, we provide extra customized procurement services with the most superior and comprehensive supply chain sources.
Leveraging state-of-the-art automation, massive production scales, and rigorous quality assurance infrastructure.
Our state-of-the-art production base integrates Class 100,000 cleanrooms, automated bioreactors, and multi-stage crystallization suites to ensure uninterrupted bulk wholesale delivery of Pseudouridine and Uridine intermediates.
Every batch undergoes rigorous quality testing including HPLC-UV-MS, 1H/13C/31P NMR, Karl Fischer water determination, heavy metal ICP-MS, and bacterial endotoxin testing (LAL assay).
By synthesizing key precursors in-house (D-ribose, uracil variants), Gentolex mitigates geopolitical supply chain risks, offering price stability and guaranteed supply capacity during global demand surges.
Gentolex’s goal is to create opportunities connecting the world with better services and guaranteed products. Up to date, Gentolex Group has been serving customers from more than 10 countries, specially, representatives are established in Mexico and South Africa. Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
Rigorous documentation support, regional logistics hubs, and international compliance frameworks for seamless cross-border sourcing.
Complete Drug Master File (DMF) availability, Certificates of Analysis (CoA), BSE/TSE-free attestations, and ISO 9001:2015 certification. Full compliance with US FDA, EMA, and NMPA filing standards for clinical-stage and commercial APIs.
Dedicated technical support hubs and sales offices in key global nodes—including established regional presence in Mexico and South Africa—providing seamless multi-currency transactions and local regulatory guidance.
Validated temperature-controlled shipping protocols (-20°C freeze and 2-8°C cold chain options) featuring real-time data loggers to guarantee structural integrity of nucleosides, nucleotides, and peptide APIs upon arrival.
Latest breakthroughs in neuroactive peptides, novel therapeutic research, and specialized API chemical syntheses.
Introduction to Selank Acetate API Selank Acetate API is a synthetic heptapeptide active pharmaceutical ingredient (API) composed of the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). Originally developed through neuropharmacological research...
View Details
Trusted Thymosin Beta-4 API Manufacturer and Global Peptide Supplier As a professional Thymosin Beta-4 API manufacturer and supplier, we provide high-quality Thymosin Beta-4 peptide API solutions for biotechnology companies...
View Details
Introduction BPC-157 API is a synthetic pentadecapeptide that has gained increasing attention in peptide research due to its potential biological activities related to tissue repair, gastrointestinal protection, and inflammatory regulation...
View Details
With the continuous development of neuroscience, peptide technology, and life science research, neuroactive peptides have become an important area of scientific investigation. Semax, a synthetic peptide derived from an ACTH fragment...
View Details
SS-31 (Elamipretide) API SS-31 API, also known as Elamipretide, MTP-131, Bendavia, and SS31, is a synthetic mitochondria-targeting tetrapeptide designed to bind cardiolipin in the inner mitochondrial membrane...
View DetailsTechnical clarity on purity grades, analytical verification methods, commercial packaging, and cGMP compliance.
Explore our expanded API portfolio, specialized peptide raw materials, and high-purity chemical components.
